The Punjab government on Sunday said it has received the Indian Council of Medical Research (ICMR) approval to undertake clinical trials for plasma therapy on COVID-19 patients.
The trial is expected to commence shortly, Additional Chief Secretary Vini Mahajan said.
The hospitals which have partnered to undertake the clinical trial of convalescent plasma therapy are the government medical college in Amritsar and Patiala, Guru Gobind Singh Medical College and Hospital in Faridkot, Sri Guru Ram Das Institute of Medical Sciences and Research at Amritsar, the Christian Medical College and Hospital, the Dayanand Medical College and Hospital and Satguru Partap Singh Hospital in Ludhiana.
The therapy involves infusing patients suffering from COVID-19 with plasma from recovered patients.
The inter-institution coordination would be done by principal investigators who would also ensure that the entire trial is conducted in strict accordance with the ICMR protocol at each institution, a government release said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app